

2015 Election Candidates Platform and Personal Statements

President-Elect 2015



Michael J. Bennett PhD, FRCPATH, DABCC, FACB, is Professor of Pathology and Laboratory Medicine at the University of Pennsylvania and Chief of Laboratory Medicine and Director of Clinical Chemistry and the Metabolic Disease Laboratory at The Children's Hospital of Philadelphia. He also holds the Evelyn Willing Bromley Endowed Chair in Clinical Laboratories and Pathology. He obtained his Ph.D. at the Sheffield University, UK in medical enzymology. His clinical chemistry training was with the Sheffield Central Hospitals (UK). Prior to taking up his present position in 2004, Dr. Bennett was Professor of Pathology and Pediatrics at the University of Texas Southwestern and Director of Clinical Chemistry at Children's Medical Center of Dallas.

A member of AACC since 1993, Dr. Bennett has also been a long-time member of the ACB. Dr. Bennett was active with the Texas Section AACC, serving many roles including Chair (1999), Nominating Committee (1996-7, Chair, 2000) and Membership Chair (1995). At the Division level, he is an active member of the Pediatric, Maternal Fetal Division where he has also served in numerous capacities including Chair (1998-9), Chair of the Scientific Program Committee (1994-6) and Chair, Nominating Committee (2000-1). He is currently Chair-Elect of the Proteomics and Metabolomics division. He was a member of the AACC Annual Meetings Organizing Committee, 2008. Dr. Bennett is a past member of the Board of Directors, NACB (2004-2006) and was NACB President in 2013, the Board of Directors AACC (2006-2008) where he is currently AACC Treasurer. He was an executive member of the Board of Directors of ABCC, and sat on the ABCC Credentials Committee. He was also a member of the NACB Education and Scientific Affairs Committee, where he chaired the expanded newborn screening LMPG. He chaired the Pediatric Reference Range Committee of AACC and serves as the AACC liaison with the March of Dimes Newborn Screening Quality Improvement Committee.

Dr. Bennett has received numerous awards including the Outstanding Clinical Chemist Award, Texas section (2000) the Award for Outstanding Contributions to Pediatric Clinical Chemistry, Pediatric and Maternal-Fetal Division (2001) the Distinguished Scientist Award of the NACB (2003) the AACC award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research (2007). He received the AACC/ACB Transatlantic Lectureship Award (2008) and is the recipient of the 2015 NACB Professor Alvin Dubin Award for Service to the Academy.

In addition to his role as an active clinical chemist, Dr. Bennett's research includes investigation of inborn errors of energy metabolism and pediatric neurodegenerative

diseases. He has published 275 peer-reviewed scientific papers, reviews and book chapters and two podcasts on newborn screening for Clinical Chemistry. He has organized numerous national and international congresses based on broad educational content and on his research. He reviews manuscripts for more than thirty journals and is currently on the editorial boards of Clinical Chemistry, Annals of Clinical Biochemistry, Journal of Inherited Metabolic Diseases, and Molecular Genetics and Metabolism.

PLATFORM STATEMENT

It is a great privilege and honor to be nominated as a candidate for President-Elect of the world's leading clinical laboratory organization. My many involvements with local section and division activities and my experience on many national committees have given me a great deal of insight into why the association is strong. I believe that my career-long involvement with clinical laboratory service, education and research places me in a strong position to truly understand the needs of everyone in our profession. The years that I have spent representing my local section, my division and the national AACC, including my present tenure on the Board of Directors as Treasurer, positions me to understand the issues that need to be resolved by future presidents. This experience will ensure that, if elected, I will serve the entire membership effectively.

The strength of AACC comes from the commitment of its leadership in promoting the strategic initiatives. One of the initiatives is to advance the science and technology of our profession. The two brightest jewels in the AACC crown are the annual meeting and Clinical Chemistry Journal. These are our flagships for promoting the science and technology. It is important that the Annual Meeting continues to provide the highest level of education and feedback regarding technological advances in our profession and provides this information such that our members are fully aware of the advances that impact their daily lives. It is also important that the Board and President recognize that not all members are able to attend the Annual Meeting. It is vital to continue to provide the highest quality of alternative teaching programs including web-based conferencing for these members.

A second important initiative is to advance the profession. My experience has taught me that as providers of critical clinical services, we are not always seen as such by other groups who have more direct patient exposure. If elected, I will make it a personal goal for the association to continue to develop closer links to other health care providing professional groups. This will involve providing continued support for the important AACC initiative built around the "Task Force on Laboratorians as Consultants". This program is designed to raise the profile of the profession. If elected, I will ensure that the significance of the professional clinical laboratorian is continued to be promoted within the health care framework. To this aim, I will continue to strongly support AACC developed initiatives to visit government to promote the importance of our profession as we did in 2014 with visits to promote Newborn screening and Laboratory Developed Tests.

This type of activity also helps promote the global role of the profession. I will continue to support presentation of our academic and teaching activities globally, particularly in developing countries where clinical laboratory medicine is not yet sufficiently advanced.

I will also support the goal of advancing clinical science. We can only continue to do this by embracing the many technological changes that are taking place. I want to see clinical chemists developing as leaders in the new fields of proteomics, pharmacogenomics and disease biomarker discovery. I will support programs that are designed to promote this high level of clinical science and encourage our members to become proficient in these areas.

During my tenure on the Board of Directors, it has become clear that one of our biggest concerns is recruitment to replace the increasing numbers of members who are retiring. With fewer new members to train and develop new technologies, advancing laboratory practice could be a difficult initiative. If elected, I will develop better ways to promote the profession at the post-graduate level so that recent graduates become aware of these very important career opportunities. This may be done by a concerted effort from all of the COMACC-accredited fellowship programs working together to define the exact numbers of fellowship positions are available each year and to make them competitive. I will also continue to provide the highest level of support for our younger members through SYCL which I recognize as the basis for our professional future.

In conclusion, I firmly believe that global and internal education, embracement of new science, recruitment of new members and advocacy are the most important areas that future AACC Board and Presidents need to continue to address going forward.



Elizabeth L. Frank, PhD, DABCC, FACB, is an associate professor of pathology at the University of Utah Health Sciences Center, and a medical director at ARUP Laboratories in Salt Lake City, Utah. Dr. Frank obtained a doctorate in organic chemistry from the University of Colorado at Boulder and did postdoctoral research at the University of Colorado Health Sciences Center. She was a faculty member of the Department of Chemistry at St. Cloud State University in St. Cloud, Minnesota, for six years. In 2001, she completed a postdoctoral fellowship in clinical chemistry and was certified as a diplomate of the American Board of Clinical Chemistry. Dr. Frank was accepted as a fellow of the National Academy of Clinical Biochemistry (NACB) in 2001.

Dr. Frank has been the co-director of the ComACC-accredited Postdoctoral Training Program in Clinical Chemistry at the University of Utah since 2002 and has directed the training of 15 clinical chemistry fellows. At ARUP Laboratories, a national reference laboratory operated by the University of Utah, she directs the Analytic Biochemistry and the Calculi and Manual Chemistry Laboratories, and is co-medical director of the Mass Spectrometry Laboratory. Dr. Frank guides research and method development for these laboratory sections that provide testing for biogenic amines, calculi, porphyrins, and vitamins. In addition, she is the Chair of the Capital Equipment Committee and a member of the Financial Planning Committee. Dr. Frank's clinical and scientific interests are focused on measurement of small molecules using high performance liquid chromatography and mass spectrometry; biochemical assessment of nephrolithiasis risk; determination of calculi composition; and use of laboratory test results to evaluate health status and identify disease.

Since joining AACC in 1985, Elizabeth has been a very active member. She served a three-year term as an elected AACC Board member (2008-10) and was Secretary of the organization from 2011 through 2013. As Secretary, Dr. Frank was a member of the Board of Directors, the BOD Executive Committee, the Finance Committee, and an *ex officio* member of the House of Delegates Steering Committee. She has worked on a number of association committees and task forces, including the Bylaws Advisory Group, the Executive VP/CEO Search Committee, and the New Journal Task Force. In addition, Dr. Frank served on the Annual Meeting Abstract Review Subcommittee from 2000-06 and 2011-13, as a judge for the Student Research Awards at the Annual Meeting (since 2001), and was a member of the 2015 Annual Meeting Organizing Committee. She was Chair of the Rocky Mountain Local Section from 2004 to 2006 and Coordinator for the Rocky Mountain Annual Spring Meeting in 2005. Dr. Frank belongs to the Nutrition, Mass Spectrometry and Separation Sciences (MSSS), and History of Clinical Chemistry Divisions. She is the current Secretary of the History Division.

Dr. Frank is a fellow of the NACB and has been active in Academy leadership, serving as a member and Chair of the Awards Committee (2002-08) and as a member of the Distinguished Abstracts Review Committee (2004-13). She served on the Commission on Accreditation in Clinical Chemistry (ComACC) as Commissioner (2005-08), Vice President and Chair of Programs (2008-10), and President (2010-11). Dr. Frank served a six-year term on the American Board of Clinical Chemistry (ABCC) as a Board

Member (2005-09) and Chair of the Chemistry Examination Sub-Committee (2009-10). From 2005-2008, she was the Secretary-Treasurer of the Academy of Clinical Laboratory Physicians and Scientists (ACLPS). She received the ACLPS Gerald T. Evans Award for Outstanding Leadership and Service in 2014.

PLATFORM STATEMENT

Thirty years ago I completed a clinical internship in medical technology and joined AACC. It was a fortunate choice. The AACC has been a valuable resource to me throughout my career. In recent years, I have been privileged to be involved in the leadership and governance of AACC as we prepared for the challenges of a changing healthcare environment. Careful planning revealed a vision for the future and a strategy to achieve our common goal to advance the practice and profession of clinical chemistry and laboratory medicine, which has been implemented with positive results. The AACC has shown the strength of its members as an organization that has the breadth, depth, and resilience to lead the clinical chemistry profession in a period of continuing challenges. Our current strategic framework sustains our established programs, such as the *Clinical Chemistry* journal, the Annual Meeting & Clinical Lab Expo, Lab Tests Online, SYCL, and the Emerging Countries Program, and extends our contribution to the profession of clinical laboratory science through several new initiatives. Implementation of these innovative programs has renewed energy for the association, its members, and the profession. This achievement isn't an end; rather it is a first step into the future.

Of the many capable members of AACC, I am particularly excited by the enthusiasm and talent of the younger clinical chemists entering the field. As a female scientist, I am especially pleased to see the increasing number of women who have joined the organization in the last decade. This new generation of laboratory scientists has contributed much to the success of the organization and they will continue to strengthen the AACC throughout their careers.

Within the context of transition and renewal, I am excited to run for AACC President-Elect. I am a passionate clinical laboratory scientist and committed to advancing our profession. If elected, I pledge to work with other professionals and organizations to advocate for laboratorians and to strategically promote clinical laboratory medicine.

I am honored to be selected as a candidate for President-Elect and I welcome the opportunity to serve the members of AACC in the coming years. With my extensive experience at the local, regional, and association level of AACC governance and my involvement in the leadership of other professional organizations, I believe I can make a significant contribution as president. My experiences as an AACC member, laboratorian, educator, and scientist have given me a broad knowledge of the field and have prepared me to contribute to effective leadership of the organization as we meet the challenges of the 21st century healthcare environment. Together we can provide global leadership to advance the practice and profession of clinical laboratory science and achieve the vision of "better health and healthcare through laboratory medicine."

Let's move forward – together.

TREASURER 2015



Steven Kazmierczak, Ph.D., DABCC, FACB, is a Professor of Pathology at Oregon Health & Science University and Scientific Director of Chemistry and Toxicology at OHSU Hospitals. Steven earned a B.S. in biology and chemistry from Youngstown State University in Youngstown, OH, and a Ph.D. in clinical chemistry from the Ohio State University. He completed his post-doctoral training in Biochemistry at the Cleveland Clinic Foundation.

Dr. Kazmierczak has been an active member of the AACC since 1983 and has served the AACC in a number of capacities at both the local and national level. He served as Secretary and Treasurer for the North Carolina Section from 1993 – 2001, Chair of the Pacific Northwest Section on multiple occasions, Chair of the Divisions Management Group and the Toxicology Examination Committee for the American Board of Clinical Chemistry, and as a member of the AACC Board of Directors. He is currently involved with certification activities through his participation with the National Registry of Certified Chemists. He is also active in the Clinical and Laboratory Standards Institute where he is a member of the CLSI area committee on clinical chemistry and toxicology. He has authored over 300 manuscripts, abstracts and book chapters related to clinical chemistry and laboratory medicine. He has previously served as an associate editor for *Clinical Chemistry and Laboratory Medicine*. His research interests include the development and evaluation of emerging markers of disease, statistics and quality control and point-of-care testing. In addition to his academic position at OHSU, Dr. Kazmierczak also serves as Laboratory Director for DiabetOmics Laboratories and serves on the Scientific Advisory Board for Abaxis Inc. and Becton Dickinson Co. He also is an advisor to two startup companies in Portland, OR, Gamma Therapeutics and Pacific Nanoscience.

PLATFORM STATEMENT

I am truly honored to be nominated for continued service to the AACC as Treasurer. The AACC has been my professional home organization since I joined the organization during my graduate studies at Ohio State University. As I became more and more involved in various aspects of the AACC at both the local and national level, I came to appreciate how much the AACC played a role in helping me succeed in my professional career as well as personally. The AACC has provided me with much more than I can possibly give back, which is why I feel so privileged to be nominated for election as the AACC Treasurer.

The field of Laboratory Medicine has undergone significant changes since I first joined the AACC, and the pace of change seems to be happening at ever increasing speed. The AACC needs to evolve along with the field of Laboratory Medicine in order to provide its members with the tools, skills and educational opportunities required to succeed in today's environment. The AACC needs to be well positioned financially in

order increase its advocacy efforts and to develop strategic alliances with other professional laboratory organizations on both the national and international level as it lead its members into the future. If elected, I will bring the same level of energy and dedication to the AACC and its members that I bring to my colleagues as at work.



Corinne Fantz, PhD is a Director, Scientific Affairs POCT, Roche Diagnostics Corporation, Indianapolis, IN.

PLATFORM STATEMENT

I would like to thank the nominating committee for selecting me to run for Treasurer. I have been an AACC member for 17 years and have served the organization in a variety of positions. Most recently I have been a member of the board of directors. My goal as treasurer would be to continue the sound policies that have made AACC so successful and to support new initiatives that will solidify our success for years to come. Keeping an open mind for the changing healthcare environment, I support financial changes that are more inclusive of all professional designations within laboratory medicine (including ensuring we have priced membership appropriately for the value delivered and changes to the annual meeting fee structure). There is tremendous talent in this organization and I am honored to be considered for this role.

BOARD OF DIRECTORS 2015



Linnea M. Baudhuin, PhD, DABMG is Associate Professor of Laboratory Medicine and Pathology at the Mayo Clinic (Rochester, MN) where she serves as Co-Director of the Personalized Genomics Laboratory, the Clinical Genomics Sequencing Laboratory, and Cardiovascular Laboratory. Dr. Baudhuin additionally has a joint appointment in the Department of Medical Genetics at the Mayo Clinic. Dr. Baudhuin earned her Ph.D. in Clinical Chemistry at Cleveland State University and the Cleveland Clinic Foundation, Cleveland, OH. She completed fellowships in Clinical Chemistry and Clinical Molecular Genetics at the Mayo Clinic. She is board-certified by the American Board of Medical Genetics and Genomics in the specialty of Clinical Molecular Genetics. Her clinical and scientific interests are centered on Personalized Medicine, Cardiovascular Genetics, Pharmacogenomics, Genomics Technologies, and Regulatory issues.

Dr. Baudhuin has been a member of AACC since 1998 and is actively involved in the AACC including as one of the founding members and Chair of the Society for Young Clinical Laboratorians (SYCL), Chair of the Midwest Section, multiple roles in the Molecular Pathology Division, nominating committee of the Lipoproteins and Vascular Diseases Division, and a member of the Editorial Board of *Clinical Laboratory News*. She also is an Associate Editor of *Clinical Chemistry* and Associate Editor of the *Clinical Chemistry* Trainee Council Pearls of Laboratory Medicine. Dr. Baudhuin is involved in educating AACC members and other laboratorians as a faculty member for AACC's online Molecular Pathology Course, Chair of the Molecular Diagnostics Course committee, and for her recent 2015 AACC webinar presentation on Direct-to-Consumer Genetic Testing. Dr. Baudhuin is also a member of the Association for Molecular Pathology where she served on the faculty for the Molecular Genetic Pathology Board Review Course. She has over 50 peer-reviewed publications and book chapters.

PLATFORM STATEMENT

It is truly an honor to be nominated for election to the AACC Board of Directors. The Board of Directors for AACC plays an essential role in guiding the organization and shaping its future.

As the leader and overarching voice of our profession, AACC is a powerful organization that plays a vital role in national and global healthcare. I believe that AACC needs to increase its visibility as a major player in the healthcare field and speak out on the important issues in healthcare today. It was for that reason why I wrote the editorial in *Clinical Chemistry* (June 2014) about Direct-to-Consumer genetic testing. With regulatory pressures strengthening, AACC must take a strong stance against unnecessary and redundant regulation while advocating strongly against testing that may be unnecessary or difficult to adequately interpret. AACC must increase its strategic partnerships with other professional organizations in order to advocate that

laboratory tests are not devices but part of the practice of medicine. Furthermore, with the increasing emphasis being placed on Personalized and Precision Medicine, AACC is an ideal organization to educate, inform, and further the involvement of laboratory medicine in this realm. If I were to be elected to the Board of Directors, one of my goals would be to help enhance the role of AACC and our members in these areas.

With the recognition that our profession is very broad, encompassing all specialties of clinical medicine and a vast variety of testing technologies, it is challenging for AACC to be able to comprehensively provide leadership and address all aspects of laboratory medicine. Therefore, AACC requires individuals with diverse laboratory medicine backgrounds, training, and experiences to come together and help lead it in the present and into the future. That is why, as a laboratory professional trained and experienced in clinical chemistry, molecular genetics, pharmacogenomics, genomic medicine, and personalized medicine, I bring unique qualities to the table. My additional experience managing a broad variety of topics as Associate Editor of the *Clinical Chemistry* journal, as well as my appointment to the board of editors of *Clinical Laboratory News* enhances the value that I bring. Furthermore, through my involvement in a variety of AACC sections and divisions and my role as one of the founding members and Chair of SYCL, I understand many of the issues and needs in our organization. I plan to use this knowledge to help bring about changes that will positively impact our profession. I am excited about the opportunity to serve AACC and its membership as a member of the Board of Directors. I am passionate about serving the needs of our members and enhancing patient care through AACC by helping AACC to increase its visibility and role in global healthcare through service, education, strategic partnerships, and innovative practices.



William Clarke, PhD, MBA, DABCC, received his Ph.D. in Analytical Chemistry from the University of Nebraska in Lincoln in 2000, followed by a post-doctoral fellowship in Clinical Chemistry at the Johns Hopkins School of Medicine, ending in 2002. In addition, he received an MBA focused on medical services management from the Carey School of Business at Johns Hopkins in 2007. Following his post-doctoral fellowship, he remained at Johns Hopkins, where he is an Associate Professor in the Department of Pathology, as well as the director of both Point-of-Care Testing and Clinical Toxicology for the hospital. His research interests include clinical mass spectrometry, method development and evaluation for therapeutic drug monitoring, clinical toxicology, point-of-care testing, and development/validation of biomarkers for use in drug management.

Dr. Clarke is board certified in Clinical Chemistry by the American Board of Clinical Chemistry, and is a Fellow of the National Academy of Clinical Biochemistry. He has been involved in the AACC at the Local Section Level (Capital Section Treasurer, Chair), Division Level (TDM/Toxicology Treasurer, CPOCT Chair), and National Level (House of Delegates, Government Relations Committee, Evidence-Based Medicine Committee, 2016 Annual Meeting Organizing Committee Chair). Dr. Clarke has published as author or co-author over 95 peer-reviewed manuscripts or book chapters, and is currently the Co-Editor-in-Chief of the journal *Practical Laboratory Medicine*, published by Elsevier.

PLATFORM STATEMENT

I am honored to be nominated for a position on the Board of Directors, and to have an opportunity to serve our organization and work as an advocate for the advancement of laboratory medicine. I am very fortunate to have a career in a field that is so interesting and rewarding, and that plays a vital role in patient care. As today's healthcare system continues to evolve, it is critical that we as a profession evolve with it, in order to best serve both physicians and patients.

If elected as a board member, I will work with the AACC leadership to further our strategic goals as an organization, and to advance the profession as opportunities arise. There are many ways to do this, including collaboration with industry and other medical societies, working with our divisions and local sections, and empowering SYCL members and other emerging leaders in the profession to take an active role in furthering these goals. I appreciate the opportunity, and will approach it with enthusiasm and professionalism if given the chance to do so.



Anthony A. Killeen, MB, BCh, PhD DABCC FACB, is Professor and Vice-Chair in the Department of Laboratory Medicine and Pathology at the University of Minnesota, Minneapolis, where he has also served as the Director of the Division of Clinical Pathology since 2002. Tony did his undergraduate degree (Biochemistry) and medical training at the National University of Ireland, Galway and his PhD at the University of Minnesota, where he also did residency training in Clinical Pathology and a fellowship in Chemical Pathology. He

is Board Certified by the American Board of Pathology and by the American Board for Clinical Chemistry. Between 1993 and 2002 he served as Director of Clinical Chemistry and Molecular Diagnostics at the University of Michigan in Ann Arbor. In addition to his administrative and clinical duties at Minnesota, Tony teaches medical students, residents, and fellows, and directs an NIH-funded clinical trials research laboratory. His research interests focus on clinical laboratory method quality, harmonization and accuracy. He has spoken at numerous AACC annual meetings since the 1990s.

Tony has been a member of the AACC since 1991 and has served in a variety of leadership roles: Chair of the Molecular Pathology Division (1999), member of the 2000 and 2004 Annual Meeting Organizing Committees, and Chair of the 2011 Annual Meeting Organizing Committee. Since 2013 he has served as Chair of the Program Coordinating Commission, which oversees most programming activity within the Association. He is a member of the Molecular Pathology and Management Divisions. He has also been very active in advancing the practice of Clinical Chemistry through his roles in scientific committees with the CAP.

PLATFORM STATEMENT

I am honored to run for the Board of Directors of the AACC, an organization in which I have been an active member of for nearly 25 years.

Clinical Chemistry is a wonderful field, full of exciting advances that bring developments from basic research to bear on human disease. We are privileged to live at that interface in our everyday work.

There is no doubt that we are at a time of unprecedented growth and complexity in clinical laboratory testing, and that this growth will continue. The rapid pace of change is challenging us as individuals and as an Association to deliver our knowledge and skills in new ways for patient care. I strongly believe that many of us, particularly those who work in clinical settings, need to be more involved in bringing our expertise closer to individual patients. With this in mind, I have advocated successfully for an initiative in AACC along these lines, which is known as the “Laboratorian as a Consultant”. The goal of this initiative is to emphasize our role as clinical consultants with unique expertise in clinical laboratory testing. While many clinical chemists already have an active consultative role in their work, my experience over many years has convinced me that there are opportunities for others to grow and enhance their activities in this area, and that the AACC can provide useful support for this with educational programs and

advocacy. This is the area that is of greatest interest to me, and why I am running for the Board of Directors.

Of course, AACC is a broad tent that includes members who work in academia, in hospitals and clinics, in commercial labs, and in the IVD industry. Regardless of the differences in our work settings, our common goal is to improve the lives of the patients we all serve through the application of advances in science and medicine. As an association of professionals with shared interests, we all benefit when the field advances. The role of the Board is to ensure that the AACC remains strong, the field remains vital, and that our members continue to have rewarding professional opportunities. I am fully committed to all of these.



Stephen R. Master, MD, PhD, FACB is Director of the Central Laboratory and Chief of Clinical Chemistry Laboratory Services at Weill Cornell Medical Center / New York Presbyterian Hospital as well as Associate Professor of Pathology and Laboratory Medicine at Weill Cornell Medical College (New York, NY). Previously, he spent 10 years on faculty at the University of Pennsylvania, where he was director of the Endocrinology Laboratory. He received his MD and PhD (Cell and Molecular Biology) from the University of Pennsylvania, where he also undertook his postgraduate

training as Resident and Chief Resident in Clinical Pathology and received the William Pepper Fellowship Award. He has been a member of AACC since 2004 and is a fellow of the NACB.

Steve has served in a number of local and national roles for AACC including Chair of the Philadelphia local section, Chair of the Proteomics and Metabolomics Division, and Chair of the House of Delegates. He currently serves on the AACC Governmental Relations Committee as well as the Clinical Chemistry Trainee Council Committee. He is also a member of the 2015 AACC Annual Meeting Organizing Committee, and he has previously played an organizing role in other AACC conferences (Proteomics, Oak Ridge/Emerging Technologies). Outside of the AACC, he serves as a member of the IFCC Cancer Genomics Working Group, the Harmonization Oversight Group of the International Council for the Harmonization of Clinical Laboratory Results, and the scientific committee for MSACL. He serves on the Board of Editors for *Clinical Chemistry* and is a member of the Proteomics/Metabolomics, Molecular Diagnostics, CTS, LIS/Medical Informatics, Personalized Medicine, History, and Mass Spectrometry/Separation Sciences Divisions of AACC. Steve has lectured widely on using informatics for laboratory quality control, and he has over 50 peer-reviewed publications encompassing proteomics, molecular diagnostics, and translational biomarker studies.

PLATFORM STATEMENT

It is a wonderful honor to be nominated for election to the Board of Directors. Based on my prior service as Chair of the House of Delegates, I am well aware of the dedication that the Board members have brought to serving the Association as well as the high responsibility to ensure that our AACC membership is served in the best way possible by our policies and programs.

With the many recent changes to health care, including laboratory-related changes in reimbursement, staffing models, technology, and information management, I believe that our profession stands at an important crossroads. We need to ensure that our scientific and clinical interests are well represented during governmental deliberations, and I have been excited to participate in AACC's renewed lobbying efforts as part of the governmental affairs committee. We also need to ensure that we have data to underscore the importance of the clinical laboratory to the broader healthcare system; this will ensure that we can make the best possible case to health care administrators

and financial directors about the importance of laboratory resources for the care of our patients.

Another important key to our continued success will be ensuring that our members are provided with appropriate tools so that we all can continue to embrace the very best new technologies, testing strategies, and ways of delivering information to our clinical colleagues. I strongly believe that the AACC can continue to play a leadership role through the journal (*Clinical Chemistry*), through strategic professional development programs such as SYCL and the Trainee Council, through NACB, and through the important work of the Divisions. The new technologies that are emerging—including mass spectrometry, improved and expanded point of care devices, and new ways in which patients acquire their own laboratory information—will require not only that we continue to exercise responsible clinical oversight but also that we further improve our communication with our colleagues who are involved in direct patient care. Current AACC initiatives focused on consultative laboratory medicine as well as future advances in our ability to use laboratory informatics to add value to our reports will help us to achieve these goals.

For many of us, AACC has served as a focal point for our professional lives and identities. The rich history of innovation and clinical service within the Association can serve as a great springboard as we move into an evolving future. I would be honored to be able to serve you, the members of the Association, as a Board Member during these exciting times.

NOMINATING COMMITTEE 2015



Roger L. Bertholf, PhD, DABCC, FACB, is Professor of Pathology and Laboratory Medicine at University of Florida College of Medicine, and Director of Clinical Chemistry, Toxicology, and Point of Care Testing at UF Health Jacksonville. He has been a member of the AACC since 1981. Roger has been elected to office in several professional organizations, including the Florida Board of Clinical Laboratory Personnel (Chair, 2008-10), National Academy of Clinical Biochemistry (Treasurer, 2006-08), American Board of Clinical Chemistry (Board of Directors, 2015-20), and the Association of Clinical Scientists (President, 2004-05; Treasurer 2011-14). Within the AACC, he serves on the Government Relations Committee, and chaired the Professional Practice in Clinical Chemistry Review Course Organizing Committee from 2009 to 2011; he currently chairs the NACB Awards Committee. Roger is Editor in Chief of *Lab Medicine*, published by the American Society for Clinical Pathology, Assistant Editor of *Journal of Analytical Toxicology*, and is on the editorial boards of *Annals of Clinical and Laboratory Science* and *Medscape Pathology and Laboratory Medicine*. He has received Clinical Chemist Recognition (2003, 2007) and Outstanding Speaker (2009) awards from AACC, Southeast Regional Member (2011) and President's (2014) awards from the ASCP, and Young Clinical Scientist (1999), Clinical Scientist of the Year (2003), and Diploma of Honor (2005) awards from the Association of Clinical Scientists. Roger created the AACC certificate program in laboratory statistics, and recently chaired an AACC-sponsored virtual conference on point of care testing



Barbara M. Goldsmith, PhD, FACB serves as both the Clinical Professor and Director of Point-of-Care Testing and Quality Management in the Department of Pathology, Anatomy, and Cell Biology, Sidney Kimmel Medical College and Professor and Chair of the Department of Bioscience Technologies, College of Health Professions at Thomas Jefferson University in Philadelphia, PA. The Department of Bioscience Technologies includes undergraduate and graduate programs in Medical Laboratory Science.

Dr. Goldsmith has over thirty years of experience in laboratory medicine as a laboratory Medical and Scientific Director in academic and non-academic hospitals and multi-hospital systems. Specialties include pediatric clinical chemistry, point-of-care testing, and quality management. Her responsibilities have included a number of administrative and management positions and she has held faculty positions teaching and mentoring Pathology Residents, Medical students, and Medical Technology students.

Dr. Goldsmith is a Past-President of AACC and the current President of NACB. She has served on numerous AACC Committees, most recently as Chair of the Latin American Work Group (LAWG). The LAWG provides educational opportunities and workshops to South and Central American countries. She was Chair of the 2007 AACC Annual Meeting in San Diego and served on two additional Annual Meeting Organizing Committees (AMOC). Dr. Goldsmith is a voting member of the FDA Advisory Panel, Clinical Chemistry and Toxicology and served as a member of CLIAC (CDC).



Peter Kavsak, PhD, is a Clinical Biochemist with Juravinski Hospital and Cancer Centre, in Ontario, Canada.



Larry J. Kricka, DPhil, FACB, CChem FRSC, FRCPath, is Professor of Pathology & Laboratory Medicine and Director of the General Chemistry Laboratory & the Endocrinology Laboratory at the University of Pennsylvania Medical Center. Dr Kricka has been an active AACC member since the 1980s. At the Local Section level he has served as the Chair of the Philadelphia Section. Also he has been active in the Immunology Division and the History of Clinical Chemistry Division. He was President of the AACC in 2001, and has served the Association on the AACC Board of Directors, Program Coordinating Committee, the Membership Committee, Book Committee, House of Delegates Steering Committee, and the Awards committee. In addition, he has been active on organizing committees for local, national and international scientific meetings, including the AACC Annual Meeting, the Oak Ridge Conference, and the Clinichem meeting. At the international level, Dr Kricka has served on the IFCC Executive Board and was President of the International Society for Bioluminescence and Chemiluminescence. Currently, he is a member of a joint IFCC-CLMA task force on leadership. He is a member of the Board of Editors of Clinical Chemistry and serves on the editorial boards of several other international scientific journals, and was Editor-in-Chief of Luminescence.

Dr Kricka received his DPhil from York University, England and was Reader in Clinical Chemistry at the University of Birmingham Medical Centre, England before moving to PENN in 1987. In 2002 he was a Distinguished Visiting Scholar at Christ's College, Cambridge, England. During the course of his career, his research interests have included the analytical applications of bioluminescence and chemiluminescence, analytical microchips, immunoassay and immunoassay interferences, direct-to-consumer testing and more recently, the history of laboratory medicine. He is the recipient of several AACC and international awards and has published extensively.



Nathalie Lepage, PhD, has been an active AACC member since 2001, when she joined the board of the Pediatric and Maternal Fetal (PMF) division, as a member at large. Throughout the years, she has also served as the secretary, the chair-elect, the chair, the nomination chair of the PMF division. She was also fortunate to be a member of two AACC annual meeting organization committees (AMOC). In 2009 (joint AACC/CSCC meeting, Chicago), she was the coordinator for the roundtables. In 2014 (joint AACC/CSCC meeting, Houston), she was one of two coordinators for the short courses.

Dr. Lepage is a full professor in the department of Pathology and Laboratory Medicine at the University of Ottawa, Canada. She is the Head of the Biochemical Genetics and Prenatal Screening Laboratory at the Children's Hospital of Eastern Ontario in Ottawa, Canada, the laboratory director for the Hawkesbury General Hospital, and a laboratory consultant for clinical Biochemistry for the teaching Montfort Hospital, both located in Eastern Ontario, Canada. She is a fellow from the Canadian Academy of Clinical Biochemistry (CACB) and a fellow from the Canadian College of Medical Geneticists.

Dr Lepage has also served as a leader (president and/or chair) of several other provincial and national professional associations, including the CACB and the Ontario Society of Clinical Chemists. She has received the CACB Award for Outstanding Service to the profession of Clinical Biochemistry and the Mentor of the Month Award from the AACC.

Current areas of clinical and research interests are in pediatric reference intervals, in prenatal screening for chromosomal abnormalities and neural tube defects, and in point-of-care testing.



Greg Miller, PhD, is a Professor in the Pathology Department at Virginia Commonwealth University where he serves as Director of Clinical Chemistry and Director of Pathology Information Systems. He has been a member of AACC since 1974, and has held various positions at local section, division and national levels including President in 2012. He is currently an Associate Editor of *Clinical Chemistry* and represents AACC on the US delegation to the

International Organization for Standardization Technical Committee 212, Clinical laboratory testing and in vitro diagnostic test systems. He co-chaired the AACC sponsored organizing committee that developed the International Consortium for Harmonization of Clinical Laboratory Tests and serves as Chair of the Harmonization Oversight Group for the consortium. He received the AACC's Outstanding Lifetime Achievement Award in Clinical Chemistry and Laboratory Medicine in 2007.

Dr. Miller has also been active outside AACC. He is the current President of the Clinical and Laboratory Standards Institute, and has held a number of positions in CLSI for both governance and standards development activities. Other current professional activities include: Chair of the Laboratory Working Group of the National Kidney Disease Education Program, Chair of the Working Group for Commutability of the International Federation of Clinical Chemistry and Laboratory Medicine, a member of the Accuracy Based Testing Committee of the College of American Pathologists, and a member of several other work groups for standardization and harmonization of laboratory procedures. He received the Robert Schaffer Award for Outstanding Achievements in the Development of Standards for Use in Laboratory Medicine from the International Federation of Clinical Chemistry and Laboratory Medicine in 2014.



Gary L. Myers, PhD, is Vice President, Science and Practice Affairs for AACC. Prior to joining AACC in 2010, Dr. Myers served as Chief, Clinical Chemistry Branch, Division of Laboratory Sciences and as Director, WHO Collaborating Center for Research and Reference in Blood Lipids at the Centers for Disease Control and Prevention (CDC). During his 33+ year career at CDC he directed programs to improve and standardize the laboratory measurement of biomarkers used to assess chronic disease status, particularly in the areas of cardiovascular disease, diabetes and chronic kidney disease. He was responsible for establishing the CDC Cholesterol Reference Method Laboratory Network, which serves as a model for other international reference laboratory networks. Most recently Dr. Myers co-chaired the establishment of the International Consortium for Harmonization of Clinical Laboratory Results whose mission is to provide a centralized process to organize global efforts to achieve harmonization of clinical laboratory test results. He served as Secretary of the IFCC Scientific Division and currently serves as Chair of the Joint Committee for Traceability in Laboratory Medicine. Dr. Myers has served AACC in a variety of capacities including: Chair of the 2002 Annual Meeting Organizing Committee; Chair of the Awards Committee, National Academy of Clinical Biochemistry Board of Directors; AACC Board of Directors; AACC President in 2007; and as Interim AACC CEO. He recently received the AACC's Outstanding Lifetime Achievement Award in Clinical Chemistry and Laboratory Medicine.



Nader Rifai, PhD, is a Professor of Pathology at Harvard Medical School, the Louis Joseph Gay-Lussac Chair in Laboratory Medicine, and Director of Clinical Chemistry at Boston Children's Hospital. He has been an active member of AACC for 35 y and served on its board of directors. His research focused on biomarkers of cardiovascular disease and resulted in over 350 peer-reviewed original reports. Dr. Rifai co-edited several books including the Handbook of Lipoprotein Testing. In the last decade, however, his main interest has shifted to communication of scientific information and E-learning. He is the Founder and Co-Chair of *Clinical Chemistry* Trainee Council and the Senior Editor of Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Dr. Rifai is also the Editor-in-Chief of *Clinical Chemistry*.



Mitchell G. Scott, PhD, DABCC, is Professor of Pathology and Immunology, Division of Laboratory and Genomic Medicine at Washington University, St. Louis, MO and Co-Medical Director of Clinical Chemistry and Point of Care Testing at Barnes-Jewish Hospital. He received his Ph.D. in immunology from Washington University in 1982. He is co-director of the clinical chemistry postdoctoral training program at Washington University and has trained over 70 fellows and 140 pathology residents. An active member of AACC since 1982, he was AACC Treasurer from 2002 – 2004 and President of in 2005. He was also President of the Academy of Clinical Laboratory Physicians and Scientists in 2009.

He is currently an Associate Editor for the journal *Clinical Chemistry*. Along with many collaborators he has authored 127 original, peer-reviewed scientific papers and 45 reviews/book chapters.



Donald A. Wiebe, Ph.D., DABCC, FACB is currently an Associate Professor in Pathology and Laboratory Medicine at the University of Wisconsin-Madison School of Medicine and Public Health. Don serves the University Wisconsin Hospital and Clinics as Director of the Toxicology Laboratory.

Don earned his B.S. in chemistry at the University of Wisconsin-La Crosse and his M.S and Ph.D. in organic chemistry from the University of Iowa, Iowa City. He was the director of the lipid laboratory at the University of Iowa for the Lipid Research Program for six years before entering the post-doctoral fellowship program in clinical chemistry at the University of Iowa. After completing the two-year program Don worked as a Visiting Scientist at the Centers for Environmental Health at CDC in Atlanta. Don moved back to Wisconsin in 1984 as an Assistant Professor in Pathology and Laboratory Medicine.

Don has been an AACC member since 1974 and is currently a member of several divisions (Lipoproteins and Vascular Diseases, Nutrition, and TDM and Toxicology) and an active member of the Chicago Section of AACC. Don has served on the AACC Standards Committee and was the AACC liaison to the CAP Standards Committee for several years. He previously served as a member of the AACC Nominations Committee. Don is a Diplomat of ABCC and served as the secretary-treasurer for the American Board of Clinical Chemistry. He also served on the Board of Directors for NRCC for several years. Don serves on the executive committee for the AACC Therapeutic Drug Monitoring and Clinical Toxicology Division and is currently serving as Past-Chair. In addition, Don was a founding member of the Lipids and Lipoproteins Division (now known as the Lipoproteins and Vascular Diseases Division) and served in several management capacities for the Lipids Division. Don received the Gerald R. Cooper Award from the Lipids and Lipoproteins Division in recognition of his service. Recently, Don served on Chicago Section AACC executive board and served as Chair-Elect, Chair and Past-Chair during 2002-2004. Chicago AACC Section has generously recognized Don by awarding him both the Albert A. Dietz service (2007) and the Samuel R. Natelson research (2005) awards. His primary research interests focus on numerous issues related to lipid and lipoprotein topics, 25-OH vitamin D analysis and Therapeutic Drug Monitoring needs.

Don has been a fellow of the National Academy of Clinical Biochemistry since 2000.



Jack Zakowski, PhD, FACB, is Director of Scientific Affairs and Professional Relations at Beckman Coulter in Brea, California. He received his BA in Biochemistry from UCLA and his PhD in Biochemistry from UC Davis. After completing a research fellowship in biochemical virology at the Univ of Virginia Medical School, he then completed a Clinical Chemistry training fellowship under Dr. David Bruns at the University of Virginia Hospital.

His career in the clinical diagnostics industry has been spent in R&D and product development, technical support, product evaluations, and scientific affairs, primarily in the areas of chemistry reagents and analyzer systems, automation and laboratory workflow processes, and standardization and harmonization of laboratory test results.

Dr. Zakowski has been active in several laboratory professional organizations. He has worked with AACC in various capacities at Local Section, Division, and National levels in different positions and on several committees, including two terms as Chair of the House of Delegates and ex officio on the AACC Board of Directors. He has served on 3 AACC Annual Meeting Organizing Committees, including one as overall Chair.

He has also served on the ISO Technical Committee 212 on *In Vitro* Diagnostic Products, including development of ISO 15189, the Patient Safety Task Force of the AACC Management Sciences Division, the National Kidney Disease Education Program, the National Glycohemoglobin Standardization Program, and others.

Dr. Zakowski has been active with the Clinical and Laboratory Standards Institute (CLSI) for many years. As a CLSI volunteer, he has served on a variety of document development committees, consensus committees, and most recently as part of the CLSI Board of Directors — currently as the President-Elect.